Levi Garraway, Roche CMO
Roche nabs an FDA OK for Gavreto, triggering a heavyweight bout with rivals at Eli Lilly
Four months after Eli Lilly’s Retevmo got the first FDA OK to treat RET-altered tumors, Roche and Blueprint Medicines are stepping into the ring …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
